A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
NCT07458347
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC)
- KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
- KRAS-mutant Colorectal Cancer (CRC)
- Other KRAS-mutant Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Kestrel Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Cedars-Sinai Medical Center · Los Angeles, CA
Florida · 2
- Florida Cancer Specialists · Sarasota, FL
- Moffitt Cancer Center · Tampa, FL
Massachusetts · 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital · Boston, MA
Pennsylvania · 1
- Sidney Kimmel Cancer Center · Philadelphia, PA
Texas · 2
- The University of Texas MD Anderson Cancer Center · Houston, TX
- NEXT Oncology · San Antonio, TX
Utah · 1
- Huntsman Cancer Institute, University of Utah · Salt Lake City, UT
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.